|
1
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
|
|
2
|
Pasquinelli AE, Reinhart BJ, Slack F, et
al: Conservation of the sequence and temporal expression of let-7
heterochronic regulatory RNA. Nature. 408:86–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reinhart BJ, Slack FJ, Basson M, et al:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar
|
|
5
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
6
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar
|
|
7
|
Slack FJ and Weidhaas JB: MicroRNA in
cancer prognosis. N Engl J Med. 359:2720–2722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu S, Lu Z, Liu C, et al: miRNA-96
suppresses KRAS and functions as a tumor suppressor gene in
pancreatic cancer. Cancer Res. 70:6015–6025. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suzuki A, Kusakai G, Kishimoto A, et al:
Identification of a novel protein kinase mediating Akt survival
signaling to the ATM protein. J Biol Chem. 278:48–53. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suzuki A, Kusakai G, Kishimoto A, et al:
ARK5 suppresses the cell death induced by nutrient starvation and
death receptors via inhibition of caspase 8 activation, but not by
chemotherapeutic agents or UV irradiation. Oncogene. 22:6177–6182.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suzuki A, Kusakai G, Kishimoto A, et al:
Regulation of caspase-6 and FLIP by the AMPK family member ARK5.
Oncogene. 23:7067–7075. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kusakai G, Suzuki A, Ogura T, Kaminishi M
and Esumi H: Strong association of ARK5 with tumor invasion and
metastasis. J Exp Clin Cancer Res. 23:263–268. 2004.PubMed/NCBI
|
|
13
|
Kusakai G, Suzuki A, Ogura T, et al: ARK5
expression in colorectal cancer and its implications for tumor
progression. Am J Pathol. 164:987–995. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki A, Lu J, Kusakai G, Kishimoto A,
Ogura T and Esumi H: ARK5 is a tumor invasion-associated factor
downstream of Akt signaling. Mol Cell Biol. 24:3526–3535. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen P, Li K, Liang Y, Li L and Zhu X:
High NUAK1 expression correlates with poor prognosis and involved
in NSCLC cells migration and invasion. Exp Lung Res. 39:9–17. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bell RE, Khaled M, Netanely D, et al:
Transcription factor/microRNA axis blocks melanoma invasion program
by miR-211 targeting NUAK1. J Invest Dermatol. 134:441–451. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu S, Niu N, Guo H, et al: ARK5 promotes
glioma cell invasion, and its elevated expression is correlated
with poor clinical outcome. Eur J Cancer. 49:752–763. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang XZ, Yu J, Liu HY, Dong RH and Cao
XC: ARK5 is associated with the invasive and metastatic potential
of human breast cancer cells. J Cancer Res Clin Oncol. 138:247–254.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cui J, Yu Y, Lu GF, et al: Overexpression
of ARK5 is associated with poor prognosis in hepatocellular
carcinoma. Tumour Biol. 34:1913–1918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo XG, Zou JN, Wang SZ, Zhang TC and Xi
T: Novobiocin decreases SMYD3 expression and inhibits the migration
of MDA-MB-231 human breast cancer cells. IUBMB Life. 62:194–199.
2010.PubMed/NCBI
|
|
21
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
22
|
Sant M, Allemani C, Santaquilani M, et al:
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999
Results and commentary. Eur J Cancer. 45:931–991. 2009.
|
|
23
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar
|
|
24
|
Kelly K, Crowley J, Bunn PA Jr, et al:
Randomized phase III trial of paclitaxel plus carboplatin versus
vinorelbine plus cisplatin in the treatment of patients with
advanced non-small-cell lung cancer: a Southwest Oncology Group
trial. J Clin Oncol. 19:3210–3218. 2001.PubMed/NCBI
|
|
25
|
Hennessy BT, Hanrahan EO and Daly PA:
Non-Hodgkin lymphoma: an update. Lancet Oncol. 5:341–353. 2004.
View Article : Google Scholar
|
|
26
|
Ekstrand AI, Jönsson M, Lindblom A, Borg A
and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways
in hereditary nonpolyposis colorectal cancer. Fam Cancer.
9:125–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li B, Tsao SW, Li YY, et al: Id-1 promotes
tumorigenicity and metastasis of human esophageal cancer cells
through activation of PI3K/AKT signaling pathway. Int J Cancer.
125:2576–2585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ohta T, Isobe M, Takahashi T,
Saitoh-Sekiguchi M, Motoyama T and Kurachi H: The Akt and ERK
activation by platinum-based chemotherapy in ovarian cancer is
associated with favorable patient outcome. Anticancer Res.
29:4639–4647. 2009.PubMed/NCBI
|
|
29
|
Simon PO Jr, McDunn JE, Kashiwagi H, et
al: Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel
strategy for the treatment of human pancreatic adenocarcinoma. Int
J Cancer. 125:942–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee EJ, Gusev Y, Jiang J, et al:
Expression profiling identifies microRNA signature in pancreatic
cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dillhoff M, Liu J, Frankel W, Croce C and
Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and
a potential predictor of survival. J Gastrointest Surg.
12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ji Q, Hao X, Zhang M, et al: MicroRNA
miR-34 inhibits human pancreatic cancer tumor-initiating cells.
PLoS One. 4:e68162009. View Article : Google Scholar : PubMed/NCBI
|
